EMA encourages companies to submit type I variations for 2024 by end November 2024
Submitted by Anonymous (not verified) on 15 November 2024 - 15:30
EMA encourages companies to submit type I variations for 2024 by end November 2024
Human medicines European public assessment report (EPAR): Celsunax, ioflupane (123I), Date of authorisation: 17/06/2021, Revision: 1, Status: Authorised
Submitted by Anonymous (not verified) on 15 November 2024 - 14:15
Human medicines European public assessment report (EPAR): Celsunax, ioflupane (123I), Date of authorisation: 17/06/2021, Revision: 1, Status: Authorised
Guideline on the evaluation of the benefit-risk balance of veterinary medicinal products
Submitted by Anonymous (not verified) on 15 November 2024 - 12:44
Guideline on the evaluation of the benefit-risk balance of veterinary medicinal products
Organisation chart: Human Medicines
Submitted by Anonymous (not verified) on 15 November 2024 - 12:30
Organisation chart: Human Medicines
Summary of opinion: Palforzia, 14/11/2024 Positive
Submitted by Anonymous (not verified) on 15 November 2024 - 12:18
Summary of opinion: Palforzia, 14/11/2024 Positive
Summary of opinion: Yervoy, 14/11/2024 Positive
Submitted by Anonymous (not verified) on 15 November 2024 - 12:17
Summary of opinion: Yervoy, 14/11/2024 Positive
Orphan designation: temozolomide Treatment of neuroblastoma, 21/08/2019 Positive
Submitted by Anonymous (not verified) on 15 November 2024 - 12:10
Orphan designation: temozolomide Treatment of neuroblastoma, 21/08/2019 Positive
Draft European Medicines Agencies Network Data Strategy - Increasing the value of data for the benefit of public and animal health
Submitted by Anonymous (not verified) on 15 November 2024 - 12:06
Draft European Medicines Agencies Network Data Strategy - Increasing the value of data for the benefit of public and animal health
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 November 2024
Submitted by Anonymous (not verified) on 15 November 2024 - 11:00
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 November 2024
Summary of opinion: Kevzara, 14/11/2024 Positive
Submitted by Anonymous (not verified) on 15 November 2024 - 11:00
Summary of opinion: Kevzara, 14/11/2024 Positive